Vor Biopharma Inc. (VOR) Financial Analysis & Valuation | Quarter Chart
Vor Biopharma Inc. (VOR)
VORPrice: $14.33
Fair Value: 🔒
🔒score
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33... more
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) th... more
Description
Shares
| Market Cap | $98.22M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Jean-Paul Kress |
| IPO Date | 2021-02-05 | CAGR | — |
| Employees | 159 | Website | www.vorbio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.01% | Total Yield | 0.01% |
VOR chart loading...
Fundamentals
Technicals
| Enterprise Value | $202.95M | P/E Ratio | -0.2 |
| Forward P/E | -3.76 | PEG Ratio | — |
| P/S Ratio | 2337059910447112.5 | P/B Ratio | -23399287215370.38 |
| P/CF Ratio | -73769244971323.19 | P/FCF Ratio | -73769244971323.19 |
| EPS | $-70.5 | EPS Growth 1Y | 1072.82% |
| EPS Growth 3Y | 745.04% | EPS Growth 5Y | 647.16% |
| Revenue Growth 1Y | -69.85% | Gross Margin | 0.5% |
| Operating Margin | -99.56% | Profit Margin | -664.56% |
| ROE | 2.75% | ROA | -13.9% |
| ROCE | -2.33% | Current Ratio | 9.16 |
| Quick Ratio | 9.16 | Cash Ratio | 8.52 |
| Debt/Equity | -0 | Interest Coverage | — |
| Altman Z Score | -28.05 | Piotroski Score | 2 |